<- Go Home
INSYS Therapeutics, Inc.
On February 18, 2020, INSYS Therapeutics, Inc. went out of business. INSYS Therapeutics, Inc. engages in cannabinoids and drug delivery systems. It also develops Cannabidiol Oral Solution, a synthetic cannabidiol, for the treatment of rare childhood epilepsy syndromes that include West syndrome and childhood absence epilepsy, as well as glioblastoma multiforme, pontine glioma, and paediatric schizophrenia. The company is based in Chandler, Arizona.
Market Cap
$3.2M
Volume
765.2K
Cash and Equivalents
$36.5M
EBITDA
-$129.6M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$52.6M
Profit Margin
79.98%
52 Week High
$6.71
52 Week Low
$0.02
Dividend
N/A
Price / Book Value
-0.02
Price / Earnings
-0.01
Price / Tangible Book Value
-0.02
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$137.2M
Return on Equity
391.85%
Return on Assets
-40.20
Cash and Short Term Investments
$83.9M
Debt
$14.0M
Equity
-$163.7M
Revenue
$65.8M
Unlevered FCF
-$45.6M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium